Qu Biologics Inc.

qu biologics is a vancouver-based, private, clinical stage biotechnology company developing site specific immunomodulators (ssi), a novel proprietary immunotherapy platform. ssis are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (crohn's disease, ulcerative colitis). ssis aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. the company has initiated three clinical trials in crohn's disease, ulcerative colitis and lung cancer. backed by a prestigious group of scientific advisors and board members, qu biologics is led by a management team that includes co-founder and ceo dr. hal gunn, a physician and expert on the body's immune response to chronic disease and chief medical officer dr. simon sutcliffe, former ceo of the bc cancer agency and a distinguished clinician, scientist and leader in can